NCT02034058

Brief Summary

The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
152

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

26 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 9, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 13, 2014

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2019

Completed
4 months until next milestone

Results Posted

Study results publicly available

December 2, 2019

Completed
Last Updated

December 2, 2019

Status Verified

November 1, 2019

Enrollment Period

5.7 years

First QC Date

January 9, 2014

Results QC Date

October 10, 2019

Last Update Submit

November 27, 2019

Conditions

Keywords

Wingspan Stent SystemWingspan StentIntracranial StentIschemic StrokeIntracranial Atherosclerotic DiseaseIntracranial Stenosis

Outcome Measures

Primary Outcomes (1)

  • Rate of Stroke or Death Among Participants

    The primary endpoint in this study is the rate of stroke (ischemic or hemorrhagic) or death within 72 hours of the procedure. Ischemic stroke was defined as a neurological deficit that is thought to have an ischemic cause and is detectable on examination at least 24 hours after onset of symptoms. Hemorrhagic stroke was defined as a symptomatic intracerebral, subarachnoid, or primary intraventricular hemorrhage. The type of stroke was confirmed by imaging.

    within 72 hours of the procedure

Secondary Outcomes (4)

  • Rate of Ischemic Stroke Among Participants

    within 72 hours post procedure

  • Rate of Neurological Death Among Participants

    within 72 hours post procedure

  • Rate of Stroke Recovery Among Participants

    at 90 days post procedure

  • Rate of Stroke in the Territory of the Stented Artery Among Participants

    within 72 hours post procedure

Study Arms (1)

Wingspan Stent System

OTHER

Placement of the Wingspan Stent

Device: Wingspan Stent System

Interventions

The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.

Wingspan Stent System

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
All patients for whom treatment with the Wingspan Stent System is considered.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (26)

University of Alabama-Birmingham

Birmingham, Alabama, 35294, United States

Location

Sutter Eden Medical Center

Castro Valley, California, 94546, United States

Location

Southern California Permanente Medical Group

Los Angeles, California, 90027, United States

Location

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States

Location

UCSD Medical Center

San Diego, California, 92103, United States

Location

Santa Barbara Cottage Hospital

Santa Barbara, California, 93105, United States

Location

Mount Sinai Medical Center

Miami Beach, Florida, 33140, United States

Location

Emory University, Grady Memorial Hospital

Atlanta, Georgia, 30303, United States

Location

WellStar Health System

Marietta, Georgia, 30060, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

Cadence Health, Northwestern Medicine Central DuPage Hospital

Winfield, Illinois, 60190, United States

Location

Baptist Health Lexington

Lexington, Kentucky, 40503, United States

Location

University of Kentucky Medical Center

Lexington, Kentucky, 40536, United States

Location

University of Massachusetts, Worcester

Worcester, Massachusetts, 01655, United States

Location

St. John Hospital and Medical Center, Inc.

Detroit, Michigan, 48236, United States

Location

SSM DePaul Health Center

Bridgeton, Missouri, 63044, United States

Location

Columbia University Medical Center

New York, New York, 10032, United States

Location

University Hospital of Cincinnati

Cincinnati, Ohio, 45219, United States

Location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Oregon Health & Science University

Portland, Oregon, 97219, United States

Location

Abington Memorial Hospital

Abington, Pennsylvania, 19001, United States

Location

Tennessee Interventional Associates

Chattanooga, Tennessee, 37403, United States

Location

Valley Baptist Harlingen

Harlingen, Texas, 78550, United States

Location

Sentara Norfolk General Hospital

Norfolk, Virginia, 23507, United States

Location

University of Washington, Harborview Medical Center

Seattle, Washington, 98104, United States

Location

Multicare Medical Center

Tacoma, Washington, 98405, United States

Location

Related Publications (1)

  • Alexander MJ, Zauner A, Chaloupka JC, Baxter B, Callison RC, Gupta R, Song SS, Yu W; WEAVE Trial Sites and Interventionalists. WEAVE Trial: Final Results in 152 On-Label Patients. Stroke. 2019 Apr;50(4):889-894. doi: 10.1161/STROKEAHA.118.023996.

MeSH Terms

Conditions

Intracranial ArteriosclerosisIschemic Stroke

Condition Hierarchy (Ancestors)

Intracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesStroke

Results Point of Contact

Title
Alice Lin, Clinical Program Manager
Organization
Stryker Neurovascular

Study Officials

  • Michael J Alexander, M.D.

    Cedars-Sinai Medical Center

    PRINCIPAL INVESTIGATOR
  • Wengui Yu, M.D.

    University of California, Irvine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 9, 2014

First Posted

January 13, 2014

Study Start

December 1, 2013

Primary Completion

August 1, 2019

Study Completion

August 1, 2019

Last Updated

December 2, 2019

Results First Posted

December 2, 2019

Record last verified: 2019-11

Locations